JO
ARCT icon

John Overdeck’s Arcturus Therapeutics ARCT Stock Holding History

John Overdeck’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.33M Buy
1,091,137
+9,353
+0.9% +$73.7K 0.01% 1788
2026
Q1 		$8.35M Buy
1,081,784
+535,098
+98% +$3.9M 0.01% 1542
2025
Q4 		$3.35M Buy
546,686
+457,467
+513% +$4.94M ﹤0.01% 2060
2025
Q3 		$1.64M Buy
89,219
+2,857
+3% +$45.9K ﹤0.01% 2259
2025
Q2 		$1.12M Buy
86,362
+49,007
+131% +$580K ﹤0.01% 2176
2025
Q1 		$396K Buy
37,355
+9,795
+36% +$155K ﹤0.01% 2616
2024
Q4 		$468K Buy
27,560
+10,430
+61% +$196K ﹤0.01% 2568
2024
Q3 		$398K Buy
17,130
+3,812
+29% +$81.5K ﹤0.01% 2566
2024
Q2 		$324K Sell
13,318
-942
-7% -$28.6K ﹤0.01% 2562
2024
Q1 		$482K Sell
14,260
-11,400
-44% -$404K ﹤0.01% 2355
2023
Q4 		$809K Buy
25,660
+5,100
+25% +$121K ﹤0.01% 2201
2023
Q3 		$525K Buy
20,560
+500
+2% +$15.4K ﹤0.01% 2253
2023
Q2 		$575K Buy
20,060
+8,600
+75% +$234K ﹤0.01% 2273
2023
Q1 		$275K Buy
+11,460
New +$206K ﹤0.01% 2460
2021
Q4 		– Sell
-7,444
Closed -$356K – 4247
2021
Q3 		$356K Sell
7,444
-318,049
-98% -$14.3M ﹤0.01% 3531
2021
Q2 		$11M Sell
325,493
-67,210
-17% -$2.28M 0.03% 739
2021
Q1 		$16.2M Buy
392,703
+229,613
+141% +$13.7M 0.04% 510
2020
Q4 		$7.08M Sell
163,090
-113,228
-41% -$7.67M 0.02% 746
2020
Q3 		$11.9M Buy
276,318
+183,572
+198% +$9.11M 0.04% 453
2020
Q2 		$4.33M Buy
92,746
+69,704
+303% +$2.4M 0.02% 706
2020
Q1 		$313K Sell
23,042
-52,620
-70% -$673K ﹤0.01% 2271
2019
Q4 		$822K Buy
75,662
+60,868
+411% +$637K ﹤0.01% 2366
2019
Q3 		$152K Buy
+14,794
New +$160K ﹤0.01% 3243
2017
Q3 		– Sell
-3,186
Closed -$25K – 2724
2017
Q2 		$25K Buy
3,186
+100
+3% +$805 ﹤0.01% 2898
2017
Q1 		$25K Buy
+3,086
New +$28.6K ﹤0.01% 2827
2015
Q1 		– Sell
-4,303
Closed -$112K – 2615
2014
Q4 		$112K Buy
+4,303
New +$137K ﹤0.01% 2124

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

John Overdeck's ARCT Position: Q2 2026 in Review

John Overdeck increased its Arcturus Therapeutics (ARCT) stake by 0.86% in Q2 2026, buying an estimated $73.7K and bringing the position to 1,091,137 shares worth $7.33M. The position accounts for 0.01% of the portfolio, ranked #1788.

John Overdeck first reported a position in ARCT in Q4 2014 and has held it in 26 quarters since. The position peaked at $16.2M in Q1 2021. 133 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • John Overdeck held 1,091,137 shares of Arcturus Therapeutics worth $7.33M as of Q2 2026.
  • John Overdeck bought 9,353 Arcturus Therapeutics shares in Q2 2026, an estimated $73.7K.
  • Arcturus Therapeutics made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1788 holding.
  • John Overdeck first reported a position in Arcturus Therapeutics in Q4 2014 and has held it in 26 quarters since.
  • John Overdeck's Arcturus Therapeutics position peaked at $16.2M in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.